/
ACOG
$9.67-$0.32 (-3.58%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$194.9M
22M shares
52-week range
$4.50 – $10.00
94% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change+$2.93
Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
www.alphacognition.com- Employees
- 71
- IPO / List date
- Jun 9, 2021
- HQ
- GRAPEVINE, TX
Held by traders on TradeandTell
No one on the platform currently holds ACOG.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ACOG as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ACOG yet.
